Nancy B. Davis

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also affiliated with Vanderbilt University, Tennessee Oncology

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma”.

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Cancers(2022)10.3390/cancers14153830

N/A

0.442DataRank · unranked

18 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer(2021)10.1002/cncr.34057

N/A

0DataRank · unranked

86 citations

Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam +31 more

Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma

Cancers(2021)10.3390/cancers13061475

N/A

0DataRank · unranked

16 citations

Anupama Reddy, Stephanie O. Dudzinski, Aaron R. Lim, Ayaka Sugiura, Rachel A. Hongo +26 more

Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.431

N/A

0DataRank · unranked

10 citations

Matthew I. Milowsky, Noah M. Hahn, David J. Kwiatkowski, Alicia K. Morgans, Nancy B. Davis +10 more

Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4527

N/A

0DataRank · unranked

2 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.364

N/A

0DataRank · unranked

0 citations

Matthew D. Tucker, Hesham Yasin, Kristin Kathleen Ancell, Nancy B. Davis, Scott M. Haake +8 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155

N/A

0DataRank · unranked

56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.111

N/A

0DataRank · unranked

6 citations

Rana R. McKay, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman +14 more

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin

International Journal of Molecular Sciences(2023)10.3390/ijms242216109

N/A

0DataRank · unranked

21 citations

Caroline A. Nebhan, Sally J. York, Nancy B. Davis, Paula J. Hurley, Jennifer Gordetsky +2 more